copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Kriya Therapeutics: Gene Therapy. Redefined. Kriya is targeting diseases that impact millions of people worldwide and represent areas of high unmet need We target validated biological pathways with innovative gene therapy approaches that have the potential to deliver transformative benefits
Careers: Future of Gene Therapy - Kriya Therapeutics Careers Kriya is Changing the Future of Gene Therapy We have an ambitious set of goals, but our confidence – and our inspiration – stems from our people From California to North Carolina, our teammates bring creativity, leadership, and a spirit of collaboration to their work every day
Kriya Presents Data at the 2025 Association for Research in Vision and . . . Kriya is developing KRIYA-825, a potential one-time gene therapy for Geographic Atrophy (GA) that expresses a fusion protein designed to inhibit the activity of complement C3 and C5, with the objective of slowing GA lesion growth and vision loss
Pipeline - Kriya Therapeutics Kriya is developing a portfolio of one-time gene therapies in ophthalmology, metabolic disease and neurology
Kriya Announces Thirteen Presentations at the American Society of Gene . . . Kriya is a biopharmaceutical company developing gene therapies to address chronic diseases affecting millions of people around the world With operations in Research Triangle Park, North Carolina, and Palo Alto, California, Kriya has raised over $600 million to advance a broad pipeline of gene therapies in ophthalmology, metabolic disease and
Neurology: Gene Therapy for Trigeminal Neuralgia - Kriya Therapeutics Kriya is developing KRIYA‑748, a potential one-time gene therapy for trigeminal neuralgia that expresses a chemogenetically-gated ion channel and is designed to be administered as an injection into the trigeminal nerve, with the objective of reducing the frequency and severity of pain attacks
Kriya Highlights Positive Preclinical Data for KRIYA-586, a Gene . . . KRIYA-586 is an investigational adeno-associated virus (AAV) gene therapy product engineered to express an antibody that inhibits Insulin-Like Growth Factor 1 Receptor (IGF1R), a key target implicated in the pathogenesis of TED